JP2025513767A5 - - Google Patents
Info
- Publication number
- JP2025513767A5 JP2025513767A5 JP2024558208A JP2024558208A JP2025513767A5 JP 2025513767 A5 JP2025513767 A5 JP 2025513767A5 JP 2024558208 A JP2024558208 A JP 2024558208A JP 2024558208 A JP2024558208 A JP 2024558208A JP 2025513767 A5 JP2025513767 A5 JP 2025513767A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- antigen
- antibody
- binding fragment
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210345737 | 2022-04-02 | ||
| CN202210345737.1 | 2022-04-02 | ||
| PCT/CN2023/085417 WO2023186078A1 (zh) | 2022-04-02 | 2023-03-31 | 针对c-Met的抗体及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025513767A JP2025513767A (ja) | 2025-04-30 |
| JP2025513767A5 true JP2025513767A5 (cg-RX-API-DMAC10.html) | 2025-06-27 |
Family
ID=88199461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024558208A Pending JP2025513767A (ja) | 2022-04-02 | 2023-03-31 | ｃ－Ｍｅｔに対する抗体及びその使用 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4506361A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2025513767A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20240170835A (cg-RX-API-DMAC10.html) |
| CN (1) | CN119013297A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2023243881A1 (cg-RX-API-DMAC10.html) |
| MX (1) | MX2024012147A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023186078A1 (cg-RX-API-DMAC10.html) |
| ZA (1) | ZA202407983B (cg-RX-API-DMAC10.html) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| HN2004000285A (es) * | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
| ME01803B (me) * | 2004-08-05 | 2010-12-31 | Genentech Inc | Humanizovani anti-cmet antagonisti |
| BRPI0709917A2 (pt) * | 2006-03-30 | 2011-07-05 | Novartis Ag | composições e métodos de uso para anticorpos de c-met |
| SG188802A1 (en) * | 2008-03-06 | 2013-04-30 | Genentech Inc | Combination therapy with c-met and egfr antagonists |
| KR20130037153A (ko) * | 2011-10-05 | 2013-04-15 | 삼성전자주식회사 | 항 ｃ-Ｍｅｔ 항체 및 그의 용도 |
| KR101844479B1 (ko) * | 2011-11-17 | 2018-04-03 | 삼성전자주식회사 | 항 ｃ-Ｍｅｔ 항체 및 그의 용도 |
| EP3630844A4 (en) * | 2017-05-30 | 2021-03-03 | Chong Kun Dang Pharmaceutical Corp. | NOVEL ANTI-C-MET ANTIBODY AND USE OF IT |
-
2023
- 2023-03-31 WO PCT/CN2023/085417 patent/WO2023186078A1/zh not_active Ceased
- 2023-03-31 JP JP2024558208A patent/JP2025513767A/ja active Pending
- 2023-03-31 KR KR1020247036670A patent/KR20240170835A/ko active Pending
- 2023-03-31 AU AU2023243881A patent/AU2023243881A1/en active Pending
- 2023-03-31 CN CN202380031407.8A patent/CN119013297A/zh active Pending
- 2023-03-31 EP EP23778442.6A patent/EP4506361A4/en active Pending
-
2024
- 2024-09-30 MX MX2024012147A patent/MX2024012147A/es unknown
- 2024-10-22 ZA ZA2024/07983A patent/ZA202407983B/en unknown